Adagene Inc.

NasdaqGM:ADAG Stock Report

Market Cap: US$90.8m

Adagene Management

Management criteria checks 2/4

Adagene's CEO is Peizhi Luo, appointed in Nov 2011, has a tenure of 13.08 years. directly owns 3.25% of the company’s shares, worth $2.95M. The average tenure of the management team and the board of directors is 6.2 years and 3.1 years respectively.

Key information

Peizhi Luo

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.1yrs
CEO ownership3.3%
Management average tenure6.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Oct 10
Adagene Inc. (NASDAQ:ADAG) Surges 26% Yet Its Low P/S Is No Reason For Excitement

The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Oct 05
The Consensus EPS Estimates For Adagene Inc. (NASDAQ:ADAG) Just Fell Dramatically

Adagene ADR GAAP EPS of -$0.87 misses by $0.45, revenue of $3.93M misses by $9.82M

Aug 30

Micro-cap Adagene surges after hours on $10M share buyback

Jun 29

CEO

Peizhi Luo (58 yo)

13.1yrs

Tenure

Dr. Peter P. Luo, PhD, also known as Peizhi, is the Founder of Adagene Inc. and serves as its Chief Executive Officer since November 2011 and Director since February 2018. He serves as President of R&D at...

Leadership Team

NamePositionTenureCompensationOwnership
Peter P. Luo
Co- Founder13.1yrsno data3.25%
$ 3.0m
Man Kin Tam
CFO & Director5.3yrsno datano data
Ling Zhou
Executive Director & Head of Human Resources5.2yrsno datano data
Jc Xu
Chief Strategy Officer & Head of Regulatory Affairsless than a yearno datano data
Qinghai Zhao
Chief Manufacturing Officer4.2yrsno datano data
Yan Li
Senior Vice President of Bioinformatics & Information Technology13.1yrsno datano data
Xiaohong She
Senior VP & Head of Clinical Operations13.1yrsno data0.094%
$ 85.6k
Guizhong Liu
Senior Vice President of Early Drug Discovery9.2yrsno datano data
Alexander Goergen
VP & Head of Business Development7.2yrsno datano data
Jiping Zha
Executive Vice President of Clinical Development3.2yrsno datano data
Songmao Zheng
VP and Head of Clinical & Quantitative Pharmacologyno datano datano data

6.2yrs

Average Tenure

55yo

Average Age

Experienced Management: ADAG's management team is seasoned and experienced (6.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter P. Luo
Co- Founder6.8yrsno data3.25%
$ 3.0m
Man Kin Tam
CFO & Director3.8yrsno datano data
Li Zhu
Independent Director1.3yrsno datano data
Steven Alan Fischkoff
Member of Scientific & Strategic Advisory Board3.3yrsno datano data
Robert Jay Spiegel
Member Scientific and Strategic Advisory Board3.3yrsno datano data
Mervyn J. Turner
Independent Director1.7yrsno datano data
Cuong Viet Do
Independent Director2.1yrsno datano data
David R. Gandara
Member Scientific & Strategic Advisory Board2.9yrsno datano data
Yumeng Wang
Director1.7yrsno datano data
Aurelien Marabelle
Member of Scientific & Strategic Advisory Board1.8yrsno datano data
Yiu Leung Cheung
Independent Director3.8yrsno datano data
Stanley Frankel
Member Scientific & Strategic Advisory Board3.3yrsno datano data

3.1yrs

Average Tenure

65yo

Average Age

Experienced Board: ADAG's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adagene Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Claire WangChina Renaissance Securities
Bing ZhaoChina Renaissance Securities
Ziyi ChenGoldman Sachs